Seonix Bio has developed a genetic risk score for primary open angle glaucoma, known as SightScore. Based on world-leading research published in Nature Genetics, SightScore scans an individual’s genome for over 2,500 genetic variants (SNPs) and positions them on a genetic risk spectrum relative to the population, enabling provision of an individual’s risk of developing glaucoma and a range of clinically relevant risk information relating to disease progression. SightScore is in development for the clinic and currently available to improve identification of high risk patients for clinical trials.